GE Healthcare’s latest innovations may help clinicians with more accurate, faster diagnosis and treatment

GE Healthcare’s latest innovations may help clinicians with more accurate, faster diagnosis and treatment

GE Healthcare’s latest innovations may help clinicians with more accurate, faster diagnosis and treatment

The FINANCIAL -- Sweden -- GE Healthcare shares a suite of advances in imaging quantitation that may help clinicians diagnose disease earlier, deliver more personalised treatment and speed up care at the 27th annual meeting of the European Association of Nuclear Medicine (EANM), 18-22 October, in Gothenburg, according to General electric.

Valérie Brissart, Europe Regional Marketing Director MICT, says: “We strive to develop systems that meet the rising quantitation needs of our customers so that they can deliver better personalized care for patients. Improved outcomes are a priority to them.”

GE Healthcare innovations on show at EANM this year include:

Discovery IQ platform is a new PET/CT system increasingly sensitive to detecting small forms of disease and built to provide consistent SUV (standardised uptake value) measurements so you can trust what you see, making it an essential tool in providing personalized care from disease detection through treatment assessment. With the highest National Electrical Manufacturing Association (NEMA) sensitivity (up to 22 cps/kBq) and the largest axial field-of-view (up to 26 cm) in the industry1, Discovery IQ can image with both half the PET dose and half the scan time2. Discovery IQ offers smaller lesion detection with our new Q.Clear next-generation PET reconstruction technology. Q.Clear provides up to 2 times improvement in PET quantitation accuracy (SUVmean) and up to 2 times improvement in image quality (SNR). Delivering consistent quantitative SUV measurements enables fast and efficient reading for greater confidence in evaluating a patient’s response to cancer treatment.

Professor Frédéric Courbon from Institut Univeristaire du Cancer de Toulouse, France, where the Discovery IQ has been installed since July 2014, explained: “The Discovery IQ represents an important improvement for the management of our patients. This technology makes it possible to perform exams with increased PET sensitivity allowing us to reduce both the PET injected tracer dose and acquisition time. Combining this new generation of PET/CT system with Q.Clear allows us to obtain even better image quality with more accurate quantitative data.”

GE Healthcare and Karolinska University Hospital in Stockholm, Sweden, have established a partnership with the goal of improving the efficiency of the care pathway for pelvic cancer patients. GE Healthcare will be providing consultancy services, tools for healthcare analytics and a PET/CT imaging platform.  The use of PET/CT technology has a key role in the cancer patient pathway, from diagnosis, through to disease staging and treatment monitoring, according to General electric.